# Rejoni

**Canonical:** https://apis.io/providers/rejoni/  
**Website:** https://rejoni.com/  
**APIs profiled:** 0

Rejoni, Inc. is a privately held, clinical-stage women's health medical device company founded in June 2020 by serial entrepreneur Amar Sawhney, PhD and Pramand LLC, and headquartered at 201 Burlington Road in Bedford, Massachusetts. It develops proprietary hydrogel-based biomaterial therapies for gynecological surgery, with a stated mission of protecting, preserving and healing the uterus. Its lead product, the Juveena Hydrogel System, is designed to prevent the formation and reformation of intrauterine adhesions (IUAs) — the scar tissue that forms after transcervical procedures such as dilation and curettage, myomectomy or treatment of heavy bleeding, and a leading cause of infertility and abnormal uterine bleeding. The system pairs a low-profile proprietary transcervical catheter with two liquid precursors that cross-link on delivery into a soft, temporary hydrogel implant that mechanically separates the uterine walls during healing and then resorbs on its own in roughly two to three weeks, about one menstrual cycle, so no removal procedure is required. Juveena is investigational only and pending FDA approval; the FDA filed Rejoni's premarket approval (PMA) application in January 2026, and the company completed patient enrollment in its US IDE pivotal study. Rejoni closed a $25 million financing in June 2026 with ClavystBio, Amed Ventures, Ascension Ventures, Catalyst Health Ventures, Delos Capital, FemHealth Ventures, Iyengar Capital and Sparta Group, and appointed women's health MedTech leader John Nealon as chief executive officer in May 2026. Rejoni runs no developer program and publishes no public API: its entire web presence is a small Webflow marketing site, and probes for OpenAPI, Swagger, GraphQL, MCP, llms.txt and every /.well-known/ discovery path returned HTTP 404 against a verified real-404 origin, while api./developer./docs./app./portal.rejoni.com resolve only to a wildcard A record with no listener answering on either port 80 or 443.

## Kin Score — 6.9 / 100 (minimal)

Scored 2026-08-19 under rubric 0.12.0. Trend: flat (-1.6 from 8.5).

| Facet | Score |
|---|---|
| Discoverability | 57.4 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Contract Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 0.0 |
| Commercial Clarity | 10.5 |
| Access Clarity | 10.5 |

Regulatory layer — **Health**: 12.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| Reversibility Documented | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Security (1)

- **Rejoni Domain Security** — TLSv1.3 · HSTS · DMARC

## Tags

Company, Medical Devices, Women's Health, Healthcare, Biomaterials, Life Sciences, Surgery, Clinical Trials, MedTech

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/rejoni/). Scores are computed from the provider's own public artifacts under a published rubric.